Krystal Biotech R&D chief sells 25K shares
Krystal Biotech’s President of R&D and ten percent owner sold 25,000 shares under a completed Rule 10b5-1 trading plan while retaining significant trust-held positions.
Rhea-AI Filing Summary
Krystal Biotech, Inc. (KRYS) insider Suma Krishnan, a director, President of R&D, and ten percent owner, reported open-market sales of 25,000 shares of common stock on September 4, 2026. The sales were executed in multiple trades at prices within ranges from $353.98 to $366.91 per share and were made under a Rule 10b5-1 trading plan adopted on September 4, 2025, which has now reached its maximum share amount and terminated. Following these transactions, Krishnan continues to hold shares indirectly through several family trusts, including 90,000 shares held by the Krishnan Spousal Trust, 51,010 shares held by the Suma Mani Krishnan Trust, and 50,000 shares held by the Krishnan Family Trust.
Positive
- None.
Negative
- None.
Insights
Analyzing...
Insider Trade Summary 10b5-1
Net Seller: 25,000 shares
Net Sell
16 txns
Insider
Krishnan Suma
Role
President, R&D
Sold
25,000 shs ($8.98M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1, F2, F3 | 520 | $354.54 | $184K |
| Sale | Common Stock F4 | 2,006 | $355.5719 | $713K |
| Sale | Common Stock F5 | 3,267 | $356.3679 | $1.16M |
| Sale | Common Stock F6 | 3,962 | $357.5742 | $1.42M |
| Sale | Common Stock F7 | 3,180 | $358.4203 | $1.14M |
| Sale | Common Stock F8 | 3,392 | $359.3862 | $1.22M |
| Sale | Common Stock F9 | 2,320 | $360.466 | $836K |
| Sale | Common Stock F10 | 1,242 | $361.61 | $449K |
| Sale | Common Stock F11 | 1,992 | $362.6527 | $722K |
| Sale | Common Stock F12 | 565 | $363.3404 | $205K |
| Sale | Common Stock F13 | 1,329 | $364.4771 | $484K |
| Sale | Common Stock F14 | 826 | $365.4139 | $302K |
| Sale | Common Stock F15 | 399 | $366.556 | $146K |
| holding | Common Stock F16 | -- | -- | -- |
| holding | Common Stock F17 | -- | -- | -- |
| holding | Common Stock F18 | -- | -- | -- |
Holdings After Transaction:
Common Stock — 1,302,145 shares (Direct);
Common Stock — 90,000 shares (Indirect, By Krishnan Spousal Trust);
Common Stock — 51,010 shares (Indirect, By Suma Mani Krishnan Trust);
Common Stock — 50,000 shares (Indirect, By Krishnan Family Trust)
Footnotes (18)
- F1. The Reporting Person may be deemed to beneficially own shares of the Issuer's common stock directly owned by the Reporting Person's spouse, Krish S. Krishnan. Such shares and transactions by the Reporting Person's spouse are not included in this Form 4, as they are being reported separately on a Form 4 filed by her spouse. The Reporting Person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein.
- F2. The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025. The Rule 10b5-1 trading plan has reached the maximum number of shares to be sold under such plan and has terminated.
- F3. The transaction was executed in multiple trades ranging from $353.98 to $354.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- F4. The transaction was executed in multiple trades ranging from $354.98 to $355.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- F5. The transaction was executed in multiple trades ranging from $355.98 to $356.96. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- F6. The transaction was executed in multiple trades ranging from $356.99 to $357.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- F7. The transaction was executed in multiple trades ranging from $357.99 to $358.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- F8. The transaction was executed in multiple trades ranging from $358.99 to $359.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- F9. The transaction was executed in multiple trades ranging from $360.01 to $361.005. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- F10. The transaction was executed in multiple trades ranging from $361.02 to $362.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- F11. The transaction was executed in multiple trades ranging from $362.02 to $363.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- F12. The transaction was executed in multiple trades ranging from $363.05 to $364.01. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- F13. The transaction was executed in multiple trades ranging from $364.07 to $365.05. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- F14. The transaction was executed in multiple trades ranging from $365.07 to $366.03. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- F15. The transaction was executed in multiple trades ranging from $366.39 to $366.91. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- F16. Held by the Krishnan Spousal Trust, an irrevocable trust established by Mr. Krishnan for the benefit of Mrs. Krishnan who serves as a co-trustee and shares voting and investment power with a 3rd party co-trustee.
- F17. Held by the Suma Mani Krishnan Trust dated July 7, 2026. The Reporting Person is the grantor and trustee of the trust, has the power to revoke the trust, and has voting and investment power with respect to the shares held by the trust.
- F18. Held by the Krishnan Family Trust. The Reporting Person and her spouse are each joint beneficial owners of the trust with joint voting and investment control.
Key Figures
Shares sold: 25,000 shares
Lowest reported trade range price: $353.98 per share
Highest reported trade range price: $366.91 per share
+4 more
7 metrics
Shares sold
25,000 shares
Total common shares sold by Suma Krishnan on September 4, 2026
Lowest reported trade range price
$353.98 per share
Lowest price in disclosed trade ranges for the September 4, 2026 sales
Highest reported trade range price
$366.91 per share
Highest price in disclosed trade ranges for the September 4, 2026 sales
Krishnan Spousal Trust holdings
90,000 shares
Common stock held indirectly by the Krishnan Spousal Trust after the reported date
Suma Mani Krishnan Trust holdings
51,010 shares
Common stock held indirectly by the Suma Mani Krishnan Trust after the reported date
Krishnan Family Trust holdings
50,000 shares
Common stock held indirectly by the Krishnan Family Trust after the reported date
Rule 10b5-1 plan adoption date
September 4, 2025
Date Suma Krishnan adopted the trading plan used for these sales
Key Terms
Rule 10b5-1 trading plan, weighted average sale price, beneficially own, pecuniary interest, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The sales reported were pursuant to a Rule 10b5-1 trading plan adopted"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average sale price financial
"The price reported above reflects the weighted average sale price"
beneficially own regulatory
"The Reporting Person may be deemed to beneficially own shares"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
pecuniary interest financial
"disclaims beneficial ownership of such shares except to the extent of her pecuniary interest"
irrevocable trust other
"Held by the Krishnan Spousal Trust, an irrevocable trust established"
An irrevocable trust is a legal arrangement where an owner transfers assets into a separate entity managed by a trustee and gives up the power to modify or reclaim those assets. For investors it matters because putting stock or other holdings into such a trust can change who controls and benefits from the assets, affect taxes and creditor protection, and influence how easy it is to sell or value those holdings—like placing valuables in a locked safe overseen by someone else.
FAQ
What insider transaction did KRYS report for Suma Krishnan on September 4, 2026?
KRYS reported that Suma Krishnan sold 25,000 shares of common stock on September 4, 2026 in a series of open-market transactions at various prices, as disclosed in a Form 4 filing.
Were Suma Krishnan’s KRYS stock sales made under a Rule 10b5-1 plan?
Yes. The filing states the sales were made under a Rule 10b5-1 trading plan adopted by Suma Krishnan on September 4, 2025. The plan has reached its maximum number of shares to be sold and has terminated.
What roles does Suma Krishnan hold at Krystal Biotech (KRYS)?
The reporting person, Suma Krishnan, is identified as a director, an officer with the title President, R&D, and a ten percent owner of Krystal Biotech, Inc.
AI-generated analysis. How Rhea-AI works. Not financial advice.
